May. 12 at 3:00 PM
$RIGL has announced that it has entered into an exclusive, global license agreement with Arvinas
$ARVN and Pfizer
$PFE , subject to regulatory clearance, to develop, manufacture and commercialize VEPPANU, the first and only FDA-approved oral PROteolysis TArgeting Chimera (PROTAC).
https://biotuesdays.com/2026/05/12/rigel-enters-into-licensing-agreement-with-arvinas-and-pfizer/